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Spinal cord stimulation (SCS) has been used for more than three decades to treat intractable pain. SCS devices and implantation methods vary, but all involve insertion into the epidural space of electrodes connected to an electrical pulse generator. Generally, a trial is performed and is followed by a permanent implantation only if successful in relieving pain. Case series have suggested that SCS is associated with pain improvement, 5 but there have been just two randomized controlled trials (RCTs) for FBSS. 6 , 7 The RCT that compared SCS with conventional medical management found that, at 6 months, a signifi cantly higher proportion found signifi cantly higher medical care costs in the fi rst 6 months in the group randomized to SCS (difference of CA $15,395). Some researchers estimate that these initial costs of SCS will be recouped by approximately 36 months postprocedure because of a reduction in pain-related health service costs. 7 , 10 , 11 However, there are few prospective data on the long-term costs of care 12 and the cost-effectiveness of SCS remains uncertain. 13 US workers' compensation recipients were not included in the RCT and have worse outcomes from a variety of pain treatments 14 ; therefore, the RCT results might not be applicable to this population.
In 2004, the Washington State workers' compensation program (Department of Labor and Industries [DLI]) began to cover SCS for injured workers with FBSS who met clinical criteria and agreed to participate in an independently conducted prospective cohort study. We previously reported the effectiveness results of this study, comparing patients who received trial SCS with or without permanent device implant, pain clinic (PC) evaluation with or without PC treatment, or usual care (UC; neither SCS nor PC evaluation). 15 We now report the cost-effectiveness results.
MATERIALS AND METHODS
The study methods and clinical outcomes were described previously. 15 In brief, 158 patients enrolled in the study. Inclusion criteria were: (1) Washington State workers' compensation claim for a back injury; (2) currently receiving work time loss compensation; (3) pain radiating into one or both legs for more than 6 months; (4) leg pain greater than back pain; (5) average leg pain in the last month rated more than 6 (0-10 scale); (6) no previous SCS surgery; (7) no current diagnosis of diabetes or cancer; and (8) ability to speak English or Spanish. Initially, additional inclusion criteria were age 18 to 55 years, claim duration less than 3 years, and 1 to 2 previously open lumbar spine operations during the claim. To increase enrollment, these criteria were broadened to age 18 to 60, claim of any duration, and 1 to 3 previous open lumbar spine operations during the claim.
SCS Group
Washington State physicians were informed of the study, and referred their patients who were candidates for SCS and appeared to meet the study inclusion criteria. Our research team conducted fi nal screening, consent, and enrollment procedures.
PC and UC Groups
Patients potentially eligible for the PC group were identifi ed from DLI administrative databases when they were approved for multidisciplinary PC evaluation. For the UC group, potentially eligible patients who had not been referred for SCS or PC were selected randomly from the DLI administrative database. For both groups, patients were sent a letter with study information and were telephoned by research staff for eligibility screening, informed consent, and enrollment.
Interventions
Decisions regarding treatments were left to patients and their health care providers. The physicians, working in academic and community settings, determined all SCS procedures, equipment and criteria for proceeding with a permanent implant. Similarly, in the PC group, the patients' health care providers decided whether the patient would be treated in the PC program and if so, the program length and content.
Analysis Sample
We defi ned treatment groups by the evaluation and treatment received during the year after enrollment. Primary analyses compared the SCS group (patients who received at least a trial of SCS; n = 51) with each of two comparison groups: PC group who received PC evaluation (n = 39) and UC group who received neither trial SCS nor PC evaluation (n = 68). This is similar to an intention-to-treat analysis advocated for RCTs 16 and adopted by the previous RCT of SCS versus medical management. 6 In secondary analyses, we compared costs and outcomes of the SCS subgroup who received a permanent SCS implant (n = 27) with those of the PC subgroup who received at least some PC treatment (n = 22).
At baseline, the three groups were similar in age, sex, and other characteristics. However, on average, the SCS group reported slightly more intense leg pain (mean score on a 0-10 scale = 7.7 vs. . 15 They were also more likely to have legal representation (49% compared with 26% [ P < 0.01] in the PC group and 29% [ P < 0.01] in the UC group).
Outcome Measures
Patients completed measures at enrollment and 6, 12, and 24 months. Physical functioning was assessed by the RDQ. 17 RDQ scores range from 0 to 24, with higher scores indicating greater disability. Patients rated the average intensity of their leg pain in the last month on a scale of 0 (no pain) to 10 (pain as bad as could be). Patients reported medications they took for back or leg pain more than fi ve times in the past month and the number of days they used it. The primary outcome, defi ned in the protocol, was a composite measure that, consistent with the clinical goals of SCS, defi ned success as at least 50% reduction (relative to baseline) in leg-pain intensity, a two-point or greater improvement on the RDQ, and less than daily opioid medication use. We also examined leg-pain intensity and RDQ scores separately to facilitate comparison with previous studies. The follow-up interview completion rate was 87% at 24 months. 15 
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Economic Measures
Using administrative databases, we examined medical and productivity loss costs to DLI through 24 months postenrollment. DLI pays for injury-related medical costs, including medications, hospitalizations, and outpatient and home health care. DLI also reimburses patients for some expenses incurred in receiving care. We used actual reimbursements, not billed charges, to calculate the medical costs to the payer. We estimated the cost of SCS implantation, revision, replacement, and removal procedures by summing all reimbursements on the day of the procedure.
Productivity loss costs included work time loss compensation payments to workers unable to work because of injury. The benefi t amounts to a maximum of 60% to 75% of the preinjury wage. Productivity loss costs also included "loss of earning power" payments to workers who returned to modifi ed duties at a lower wage, as well as other reimbursements made to workers judged to have permanent loss of function. Administrative data on medical and productivity loss costs were available for all participants.
Cost-Effectiveness Analyses
All costs were converted into 2007 US dollars, using the consumer price index for medical care commodities (pharmaceuticals) and medical care services (other health care). 18 Costs after the fi rst year of study enrollment were discounted at a rate of 3%. 19 We compared the unadjusted mean costs per patient for the three study groups using bootstrapping and bias-corrected accelerated confi dence intervals (CI). 20 We also calculated the incremental cost-effectiveness of SCS versus PC and UC, by estimating the cost per successful outcome ( i.e. , additional cost of SCS/additional percentage of SCS patients achieving the primary outcome) at 24 months. In secondary analysis, we calculated cost-effectiveness separately for the pain and disability components of the composite success measure.
We compared mean 24-month costs and cost-effectiveness adjusting for baseline covariates selected because they were not balanced between analysis groups at baseline or were independently associated with either the costs or effectiveness outcomes at 24 months. These covariates were medical and productivity loss costs in the year prior to enrollment and baseline patient age, 36-Item Short Form Health Survey version 2 21 Mental Health scale score, disability benefi t in addition to workers' compensation, RDQ score, leg-pain intensity, duration of work time loss compensation, and legal representation. 15 Self-reported duration of leg pain was highly correlated with duration of work time loss compensation and was not included as a covariate in the adjusted analyses. For the covariate-adjusted analyses, we adopted Bayesian methods 22 to calculate 95% credible intervals (CrI). Costs were assumed to follow a gamma distribution. Covariate adjustment for the effect measure of therapeutic success was modeled using logistic regression. The fi nal model was selected on the basis of the Deviance Information Criteria, 23 where more complex models were selected if they gave a reduction in Deviance Information Criteria of at least 3. Model convergence was achieved after 30,000 iterations and results were based on a further 60,000 iterations.
Because it is unclear how much the workers' compensation program would be willing to pay for a successful outcome, we used cost-effectiveness acceptability curves to depict the probability that SCS is the most cost-effective therapy at a wide range of thresholds ($0-250,000 per successful outcome). 
RESULTS
Cost Analysis
At baseline, the three treatment groups had similar mean medical and productivity loss costs in the preceding year ( Table 1 ). In the 24 months after enrollment, mean total medical cost per patient ( Table 2 ) was $52,091 in the SCS group (all patients who had trial SCS, regardless of whether they had a permanent implant). This was $17,291 (95% CI, $4,100-30,490) higher than in the PC group and $28,128 ($17,620-38,630) higher than in the UC group.
Twenty-seven (53%) of 51 patients who had trial SCS went on to have a permanent SCS device implanted. The total cost 
Effectiveness and Cost-Effectiveness
Few patients achieved success on the primary outcome ( Tables 3 and 4) . As reported previously, at 24 months, 5% of SCS patients, 3% of PC patients, and 10% of UC patients reported at least two-point RDQ improvement, at least 50% leg pain reduction, and less than daily opioid use (differences not statistically signifi cant). 15 Even after adjustment for baseline covariates, SCS was much more costly and only fractionally more effective than UC. Compared with UC, the incremental cost of SCS per patient achieving success on the primary outcome was very high ($334,704; Table 3 ).
of the initial SCS trial (n = 51) and permanent implantation procedures (n = 27) was $1,085,394, equivalent to $21,282 per patient. Among the 27 permanent implantation patients, fi ve had one or more revision/replacement procedures and fi ve had permanent removal procedures billed to DLI by 24 months. The total cost of all revision/replacement and removal procedures was $100,753, equivalent to $1976 per patient. Among the 39 patients evaluated at PCs, 22 (56%) received some treatment at the PC. Among the 38 PC patients with follow-up data at 6-or 12-month interview, the most frequently reported treatments received were physical therapy (74%), occupational therapy (53%), and psychological therapy (39%). Among the 66 UC patients with follow-up data, the most frequently reported therapies received were physical therapy (39%), back brace or corset (35%), and spinal injections (33%).
There were no signifi cant differences between groups in productivity loss costs ( Table 2 ) . Total unadjusted medical and productivity loss costs were highest in the SCS group, averaging $98,637 per patient over the 24 months ( vs. $84,340 and $67,292 in the PC and UC groups, respectively). After adjusting for baseline covariates, the mean medical and productivity loss costs of the SCS group were $20,074 (95% CrI, $3,840-35,990) higher than those of the PC group and $29,358 ($16,070-43,790) higher than those of the UC group. There was no evidence that the SCS group had lower medical costs than the other two groups during the second year after enrollment ( Figure 1 ) . 
Subgroup Analysis: Patients Who Received Permanent SCS Implant Versus Those Who Had PC Treatment
At 24 months, a nonsignifi cantly higher proportion of patients who had a permanent SCS implant, as compared with patients who had at least some PC treatment, achieved success on the primary outcome and two of its components:
Compared with PC, the incremental cost of SCS per patient achieving success on the primary outcome, adjusted for baseline covariates, was also high ($131,146; Table 4 ). The cost-effectiveness acceptability curve for the primary outcome ( Figure 2 A) suggests that SCS was very probably not ( < 5% probability) the most cost-effective treatment option at any threshold of willingness to pay because UC patients had much lower costs and very similar outcomes. Focusing on at least 50% improvement in leg pain at 24 months (16% of the SCS group, 15% of the PC group, and 21% of the UC group met this success defi nition) 15 did not alter the fi nding that SCS was very unlikely ( < 7% probability) to be a cost-effective therapy ( Figure 2 B) . A nonsignifi cantly higher proportion of SCS patients achieved a modest improvement at least 50% reduction in leg pain and two-point or greater improvement in RDQ score 15 ( Table 5 ). The mean cost of care in the SCS permanent implant group was $18,810 higher (95% CI, − $672-38,292) than in the PC treatment group. The incremental cost per successful outcome was in excess of $100,000 for all three outcomes ( Table 5 ) , although the confi dence intervals are very broad.
DISCUSSION
Among workers' compensation recipients with FBSS, the medical care and productivity loss costs (adjusted for baseline covariates) over 24 months for a patient who received a trial of SCS were, on average, $20,000 higher than those for a patient who received a multidisciplinary PC evaluation and more than $29,000 higher than those for a patient who received UC. Most of these additional costs refl ect the costs of SCS trials and permanent implants, which were not counterbalanced by lower medical or productivity loss costs during the 24-month follow-up. As reported previously, the SCS group did not have signifi cantly better pain, function, or opioid medication use outcomes at 24 months. 15 Therefore, we found no evidence that SCS is a cost-effective intervention for workers' compensation patients in this setting.
SCS devices are expensive and may lead to downstream costs, through adverse events and revision or removal procedures. These costs should be weighed against the potential benefi ts in terms of improvement in patient pain and function, reduced use of medications and health services, and reduced productivity losses. Technology appraisals of SCS have been limited by the paucity of RCTs and cost-effectiveness data. 25 -27 In the United Kingdom, the National Institute of Health and Clinical Excellence recommended SCS as a treatment option for chronic neuropathic pain, but called for further "observational research to generate robust evidence about the durability of benefi ts." 25 Observational research is necessary because a therapy found to be cost-effective in tightly controlled RCTs may be less effi cient when applied in the community, where patient characteristics and physician expertise vary. with the wider patient population. 31 , 32 Furthermore, workers' compensation claimants have worse outcomes than other patients after a variety of pain therapies. 33 , 34 The effectiveness of SCS may also be dependent on physician expertise in patient selection and implantation procedures, and it is possible that physicians in the RCT were more technically profi cient than those in our study.
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Rigorous RCTs are the gold standard method of determining treatment effi cacy; observational studies are graded to be of lower quality. 35 The primary limitation of observational studies is the potential for unmeasured differences between treatment groups to bias comparisons. It is possible that the lack of effectiveness and cost-effectiveness of SCS observed in our study is due to such unmeasured confounders. However, in some circumstances, observational study designs are recommended as a more feasible alternative to RCTs for health care payers wishing to provide access to a promising health technology while accumulating additional evidence. 36 Observational studies can determine whether RCT results are replicated in specifi c patient populations and settings, 28 whether short-term benefi ts reported in RCTs are durable over longer time periods, and the long-term risks and costs of care. 36 Our small sample size was another potential limitation. Nevertheless, the large additional costs of SCS and the low success rates in the SCS group, regardless of the defi nition of success, resulted in a low probability that SCS was costeffective in this setting. Our results suggest that US workers' compensation programs should not assume that the benefi ts of SCS and potential cost savings reported in the RCT would be replicated in their patient populations. The results also underscore the importance of conducting studies to assess a therapy's cost-effectiveness in actual practice settings, using actual cost data.
Our fi ndings differ from those of the RCT comparing SCS and conventional medical management for FBSS. In the RCT, 9 the per patient cost of SCS trial, permanent implantation and revision procedures (CA $18,175) was much lower than the equivalent cost observed in our study (US $23,258), despite a lower proportion of patients in our study proceeding from SCS trial to permanent implant. This large cost differential confi rms previous work comparing SCS reimbursements between Canadian and US payers. 29 It emphasizes that cost-effectiveness results from international trials cannot be assumed to apply in the US health care system. Several authors have used economic modeling to extrapolate trial results and predict the long-term effi ciency of SCS for FBSS. 10 , 27 , 30 Kumar et al , 11 using data from one cohort study, estimated that medical costs in the second year after therapy would be much higher in conventional medical management patients (CA $7,291) than in patients treated with SCS (CA $1,092). Assuming that these costs remained constant in subsequent years, they estimated that SCS would be cost saving within 3 years. Our data, on the basis of actual reimbursements, do not replicate these estimates. Medical costs in all three treatment groups exceeded US $9500 during the second year after enrollment and costs were highest in the SCS group.
Compared with the RCT, fewer SCS patients in our study had a successful trial (53% in our study vs. 92% 6 ), fewer achieved 50% reduction in leg-pain intensity at 6 months (18% 15 vs. 48% 6 ), and fewer patients with successful SCS trials and permanent implants achieved 50% reduction in leg-pain intensity at 6 months (33% 15 vs. 51% 6 ). The poorer outcomes of SCS observed in our study might be related to the patient population and setting. RCT participants are highly selected and often have better outcomes as compared 
